webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

MPB-MMAF

  CAS No.:   Cat No.: BADC-00749 4.5  

MPB-MMAF is a drug-linker conjugate for ADC by using Monomethylauristatin F (MMAF,a potent tubulin polymerization inhibitor), linked via MPB.

MPB-MMAF

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C53H76N6O11
Molecular Weight
973.22
Shipping
Room temperature, or blue ice upon request.
Shipping
-20°C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Shipping
Room temperature, or blue ice upon request.
Storage
-20°C

MPB-MMAF is a crucial drug-linker conjugate that plays a significant role in the development of antibody-drug conjugates (ADCs), which are at the forefront of modern oncological therapeutics. This conjugate combines monomethyl auristatin F (MMAF), a highly potent tubulin polymerization inhibitor, with the linker 4-(N-Maleimidomethyl)cyclohexane-1-carboxylate (MPB). MMAF's ability to disrupt microtubule dynamics effectively halts cell division and induces apoptosis in cancer cells, making it a powerful cytotoxic agent ideal for targeting cancerous tissues. The innovative use of MPB as the linker ensures that MMAF is delivered specifically to cancer cells, minimizing systemic exposure and reducing side effects often associated with conventional chemotherapy.

The MPB linker in MPB-MMAF is designed to provide a stable attachment between the cytotoxic drug (MMAF) and the targeting antibody component of an ADC. This stability is crucial for maintaining the integrity of the ADC as it circulates within the bloodstream, preventing premature release of MMAF and ensuring that the drug is only activated upon reaching the target site. The MPB linker includes a maleimide group, which allows it to form a covalent bond with thiol groups on antibodies. This binding capability is central to the conjugate's ability to deliver the payload directly to tumor cells that express specific antigens, ensuring high precision in targeting and enhanced therapeutic efficacy.

One of the significant applications of MPB-MMAF is its use in treating various types of cancer, including those that are resistant to standard therapies. Since MMAF is non-cell-permeable, it remains within the targeted cancer cell once internalized, providing a means of exerting its cytotoxic effects without affecting surrounding healthy tissue. This selective activity makes MPB-MMAF especially valuable in the treatment of solid tumors and hematological malignancies where targeted cellular destruction is essential. By leveraging the high potency of MMAF and the specificity afforded by the MPB linker, clinicians can achieve more effective cancer cell eradication while preserving patient quality of life.

Additionally, MPB-MMAF is part of ongoing research and clinical trials, where its design and application continue to be optimized. Studies focus on expanding the use of this conjugate to more cancer types by exploring new antibody targets and improving the linker chemistry for even greater selectivity and efficacy. Researchers are also investigating combination therapies, integrating MPB-MMAF-based ADCs with other modalities such as immune checkpoint inhibitors or conventional treatments to enhance overall response rates. This integration of MPB-MMAF into comprehensive cancer care strategies highlights its potential to significantly impact the future of personalized medicine, providing tailored approaches to treatment that significantly reduce the burden of cancer on patients.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Oportuzumab monatox | MC-vc-PAB-(PEG2)-duocarmycin TM | MPB-VC-PAB-DM1 | MC-MMD-10 | MA-PEG4-vc-PAB-DMEA-duocarmycin TM | DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin SA | C-lock-PEG4-MMAE | DBCO-PEG4-vc-PAB-Duocarmycin TM | OSu-PEG4-vc-PAB-DMEA-Duocarmycin SA | OSu-PEG4-vc-PAB-DMEA-Duocarmycin TM | MPB-MMAF
Send Inquiry
Verification code
Inquiry Basket